Vital Signs Podcast: EBR's major milestones in WiSE CRT commercialisation
Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath.
In this episode Nadine chats to John McCutcheon, the President and CEO of EBR Systems (ASX:EBR).
EBR is focused on its lead technology, the WiSE CRT System, an innovative device designed to overcome the limitations of conventional Cardiac Resynchronisation Therapy (CRT) and is the only leadless left ventricular endocardial pacing (LVEP) device on the market.
The company recently received FDA approval for the device in the US, opening the door to a mega market opportunity in one of the worlds largest healthcare markets.
Earlier this month, the first two US commercial patients were treated with WiSE ahead of the company's reimbursement milestones, further demonstrating the clinical importance of the device.
In this episode McCutcheon explains the significance of the technology, the reimbursement scheme and outlines the next steps for EBR as it prepares for commercial roll out.
This podcast was developed in collaboration with EBR Systems, a Stockhead advertiser at the time of publishing.
The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.
Originally published as Vital Signs Podcast: EBR's major milestones in WiSE CRT commercialisation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
Lunch Wrap: ASX smashes fresh record as earnings season runs hot
ASX hits fresh high as Origin powers up
 Westpac jumps on big quarter Bitcoin smashes record, Ethereum eyes personal best next The ASX was strutting into Thursday lunchtime in the east with a 0.7% lift, rewriting the record books yet again. Wall Street also rallied overnight, buoyed by the growing belief the Fed's about to hand out rate cuts like a spring clearance sale. Bitcoin burst into the party, too, clocking another all-time high and flexing at US$123,675 at the time of writing, while Ethereum is lurking just shy of its own record of US$4,878 (set four years ago). Back home, it was the utilities sector leading the charge, up on the back of Origin Energy's (ASX:ORG) blockbuster 5% surge. Origin's LNG cash machine kept humming in FY25, lifting profit, fattening franked dividends, and easily outshining softer energy retail as it handed shareholders a juicier 60c payout. Banks also staged a comeback after Wednesday's bruising. Westpac (ASX:WBC) was the headline act, rocketing 7% thanks to a 14% jump in third-quarter profit and a cool $10 billion lift in deposits. Suncorp Group (ASX:SUN) rose 3% on a 52% profit leap in its full-year results thanks to its ANZ bank sale gains. Elsewhere in earnings season madness, Telstra (ASX:TLS) was the lone sector buzzkill for telcos, down 3% despite a 31% jump in annual profit to $2.34 billion and a $1 billion share buyback. Pro Medicus (ASX:PME) impressed with a 40% profit jump in its full-year numbers and $520 million in fresh US contracts, lifting shares 5%. Temple & Webster (ASX:TPW) jumped 7% after full-year revenue grew 21%. Apparently we still can't resist a good online furniture binge. But not everyone was kicking goals. South32 (ASX:S32) slid 5% after slapping a US$372 million impairment on its Mozal aluminium smelter in Mozambique. Without a new power deal, the operation could shut in March, it said. ASX LEADERS Today's best performing stocks (including small caps) intraday: Security Description Last % Volume MktCap GGE Grand Gulf Energy 0.002 100% 800,584 $2,820,425 MRD Mount Ridley Mines 0.005 80% 30,230,623 $1,946,223 ATV Activeportgroupltd 0.016 68% 59,216,662 $6,526,282 MEL Metgasco Ltd 0.003 50% 100,000 $3,674,173 OD6 Od6Metalsltd 0.100 47% 19,995,087 $10,911,821 BPH BPH Energy Ltd 0.013 44% 19,133,068 $10,964,095 BPP Babylon Pump & Power 0.007 40% 7,930,629 $19,034,455 CR9 Corellares 0.004 33% 750,000 $3,021,809 TYX Tyranna Res Ltd 0.004 33% 250,000 $10,026,464 KNG Kingsland Minerals 0.185 28% 352,638 $10,521,332 BMM Bayanminingandmin 0.165 27% 5,500,122 $14,196,703 FRB Firebird Metals 0.175 25% 3,055,947 $19,930,596 ARV Artemis Resources 0.005 25% 3,261,000 $11,462,689 DTM Dart Mining NL 0.003 25% 10,091,666 $2,396,111 OSX Osteopore Limited 0.010 25% 933,405 $1,898,080 VRC Volt Resources Ltd 0.005 25% 25,681 $18,739,398 SLM Solismineralsltd 0.135 23% 1,380,384 $15,518,820 BM8 Battery Age Minerals 0.082 22% 11,644,677 $10,170,722 BMG BMG Resources Ltd 0.012 21% 10,315,111 $8,059,773 MMR Mec Resources 0.006 20% 6,840,475 $9,248,829 SPQ Superior Resources 0.006 20% 1,487,217 $11,854,914 TML Timah Resources Ltd 0.031 19% 164 $2,307,754 ActivePort Group (ASX:ATV) has switched on Australia's first private-cloud superhighway, landing DigiCo, Equinix and NextDC as early customers just weeks after launch. Its Private-Cloud Connect delivers wholesale, fibre-based, on-demand bandwidth between branch offices and private clouds in top Aussie data centres, built for the AI era where demand for local hosting is surging. Battery Age Minerals (ASX:BM8) has confirmed Falcon Lake is more than just a lithium play, with new assays showing high-grade rubidium, caesium, tantalum and gallium alongside its already strong spodumene hits. The latest drilling backs Falcon Lake as a multi-metal prize, with standout lithium intercepts including 54.1m at 1.74% Liâ‚‚O and 55.95m at 1.47% Liâ‚‚O. With only five of 30 high-priority targets drilled and lithium prices starting to recover, the company said the project has plenty of runway for more discoveries and market upside. ASX LAGGARDS Today's worst performing stocks (including small caps) intraday: Code Name Price % Change Volume Market Cap LNU Linius Tech Limited 0.001 -50% 7,546,000 $13,002,431 ECT Env Clean Tech Ltd. 0.003 -25% 553,610 $16,061,742 PKO Peako Limited 0.003 -25% 10,670,597 $5,950,968 RKB Rokeby Resources Ltd 0.010 -23% 3,031,200 $21,253,195 CAV Carnavale Resources 0.004 -20% 858,307 $20,451,092 ERA Energy Resources 0.002 -20% 1,929,673 $1,013,490,602 CTM Centaurus Metals Ltd 0.368 -18% 1,344,178 $223,515,546 BUY Bounty Oil & Gas NL 0.003 -17% 870,000 $4,684,416 EMT Emetals Limited 0.005 -17% 1,069,204 $5,100,000 SER Strategic Energy 0.005 -17% 3,354,304 $5,020,150 SHP South Harz Potash 0.003 -17% 1,400,675 $4,415,170 AVE Avecho Biotech Ltd 0.006 -14% 99,629 $22,214,246 CR1 Constellation Res 0.120 -14% 5,000 $10,088,556 CYQ Cycliq Group Ltd 0.006 -14% 93,818 $3,223,617 OVT Ovanti Limited 0.006 -14% 1,343,942 $29,920,265 TSL Titanium Sands Ltd 0.006 -14% 410,785 $16,413,230 BEL Bentley Capital Ltd 0.013 -13% 1,550,000 $1,141,919 ANR Anatara Ls Ltd 0.007 -13% 100,000 $1,708,723 AON Apollo Minerals Ltd 0.007 -13% 512,488 $7,427,655 IN CASE YOU MISSED IT RBA rate cut: Why the cost of doing nothing just got more expensive for property investors. Parental safety and privacy concerns are fuelling growth for ASX tech stocks in the booming 'anxiety economy'. White Cliff Minerals' (ASX:WCN) first round of drilling at Rae has identified a sediment-hosted copper system, underlain by semi-massive sulphide veining. Albion Resources (ASX:ALB) has completed the sale of Mongers Lake to Capricorn Metals (ASX:CMM) for $100,000 cash and 1.4 million in shares. LAST ORDERS Lumos Diagnostics (ASX:LDX) is looking to expand its marketing presence in the US, inking a partnering agreement with US-based market access consultancy, PRO-spectus. PRO-spectus will support the marketing, market access, and reimbursement of LDX's flagship point-of-care test, FebriDx®. New Age Exploration (ASX:NAE) has welcomed financial market veteran Daniel Eddington to the board as an independent non-executive director. Eddington also serves as a non-executive director for Osmond Resources (ASX:OSM) and Jade Gas (ASX:JGH) and as a director of Sparc Technologies (ASX:SPN). VHM (ASX:VHM) is moving into a new stage of development for its heavy minerals and rare earths Goschen project, welcoming new CEO Andrew King and CFO Benjamin McCormick to the board effective October 1. Current CEO Ron Douglas will subsequently resume his non-executive director position on the board as planned, after assisting in King's transition over the next few months. At Stockhead, we tell it like it is. While Lumos Diagnostics, VHM and New Age Exploration are Stockhead advertisers, they did not sponsor this article.
News.com.au
2 hours ago
- News.com.au
Health Check: Pro Medicus banks the profits as customers go the ‘full stack'
Pro Medicus shares surge up to 7% on record revenue and earnings Tetratherix pockets $3.3 million, while Rhythm girds for a raising CEO oration inspires Starpharma share run The $32 billion market cap ProMedicus (ASX:PME) has drawn the chapter on what co-founder and CEO Dr Sam Hupert dubs 'the most successful year in the company's history by any measure'. The US-focused radiology imaging house today posted revenue of $213 million for the full year to June 30 2025, up 32%. Net earnings surged 39%, to $115 million. While the numbers were pretty much as expected, the shares surged up to 7% on the prospect of further revenue gains from newly-written contracts. The company is also expanding into areas such as cardiology and pathology – the latter of which could be two-thirds the size of the radiology market. "But it's early days." Hupert describes a 'record year of new contract wins, contract renewals and sales of additional modules'. Revenue rose in the three key jurisdictions of the US, Germany and Australia, but North America led the way with a 36% increase. The company derives about 90% of its revenue from the US. During the year, Pro Medicus won $520 million of new contracts. Yep, that's a record. These included a monster $330 million deal with Trinity Health, one of the biggest not-for-profit networks in the US. The company also signed two key renewals, totalling $130 million. Hupert says more customers are going the 'full stack', which means they are availing of the company's image viewing, archiving and workflow tools. Only the beginning? He adds that many of the recently signed contacts will come on stream 'in the next year and beyond', which means 98% of this revenue is yet to be recognised. He cites forward contracted revenue for the next five years at $948 million, up from $624 million a year ago. Despite the growth, Pro Medicus still accounts for only 10% of the US total addressable market. The company still trades on an extravagant price-earnings multiple, which implies that this 10% will become a much bigger number in the near future. 'We don't have a fixed target in mind, our aim is to get as big a percentage market share as possible,' Hupert says. 'Importantly, we do not see any technical or capacity-related reason why we will not continue to increase our market share materially from here.' Hupert says the company's recent $10 million loan facility to lung imager 4D Medical (ASX:4DX) related to the companies AI capabilities. There's the prospect of adding one or morr 4D products to the Pro Medicus stable. "But I wouldn't read more into it than that." Broker RBC says while the result was broadly in line with consensus, the company pleased with its free cash flow generation and upbeat outlook on contracts. RBC has a 'hold' rating on the stock with a 'price target' of $350. Starpharma shares take a run Starpharma (ASX:SPL) CEO Cheryl Maley's prezzo to Bioshares annual summit in Hobart last week appears to have been enough to spark a 50% share run. The contents weren't new, but Maley did outline how management had tweaked the company's strategy over the last year. Maley started in January 2024. Otherwise, Starpharma's June quarterly report showed customer receipts of $2 million, 51% higher than the March quarter. Net cash outflows were $2 million. Starpharma's reason for being is its dendrimer enhanced product (DEP) platform, which has produced the commercialised bacterial vaginosis treatment Vivagel and the germ-busting nasal spray Viraleze. Before you ask, dendrimers are nanoscale polymers aimed at improving drug efficacy and reducing side effects (such as bone marrow toxicity and hair loss). The company has oncology programs that combine the dendrimer with three existing drugs. They are irinotecan (colorectal cancer), cabazitaxel (prostate cancer and others). Management is attempting to outlicense these assets. Maley says despite considerable interest 'the licensing process has taken longer than anticipated.' She attributes this to factors including "the evolving oncology landscape shifting towards targeted treatment options and the current geo-political environment, which has impacted the biotechnology industry at large". Starpharma ended the quarter with cash of $15.5 million – enough funding for close to two years – with an expected $3.5 million R&D tax rebate yet to come. Starpharma shares today had a well-earned rest, falling around 10%. Rhythm limbers up for raising Rhythm Biosciences (ASX:RHY) shares are on trading halt pending a capital raising announcement, on or before next Monday. It's not a bad time for the company to tap the market, given its shares have gained 75% over the last month. Rhythm is developing Colostat, a blood-based cancer assay which could replace the commonly used 'poo' tests. The company also owns Genetype, a genetic risk assessment testing platform combining clinical, family history and genetic data. Rhythm bought this asset from the administrators of Genetic Technologies. Tetratherix gets a grant Of course, the best form of funding is the free variety and the recently listed Tetratherix (ASX:TTX) has come up trumps in this regard. The wound-care house has been awarded $3.3 million of non-dilutive funding, under the federal Industry Growth Program grant. Tetratherix is commercialising products based on its polymer biomaterials, which offer claimed benefits such as increased flexibility and bioresorbability. The grant will partly fund a $7.4 million project to take its Tetramatrix platform global, including expanding its production facility near Sydney Airport. The funding spans the current financial year and 2026-27. Tetratherix shares have gained a sprightly 40% since listing on June 30, the only local life sciences IPOs year to date. But if you think that's a drought, there been no US biotech IPO for six months. The last one was diseases specialist Aardvark Therapeutics, which listed on the Nasdaq in mid-February.
Herald Sun
2 hours ago
- Herald Sun
ASX rebounds toward record highs
Morning, and welcome to Stockhead's Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks off in earnest. In brief, this is what the market has been up to this morning. ASX rebounds from CBA hangover The ASX is in fine form this morning, up a chipper 0.66% in the first hour after a dour day of profit taking yesterday. Big losses in Commonwealth Bank (ASX:CBA), AGL Energy (ASX:AGL) and some of our premier mining stocks drove the market lower on Wednesday, but we're seeing no signs of that today so far. Of our 11 sectors, nine are on the up and one is dead flat, with just telecommunications sliding (-1.39%). The utilities sector is striding powerfully in the other direction, up almost 4% with some solid foundational support from our Banks (+1.1%), Gold (+0.89%) and Tech (+1.05%) indices. As for commodities, oil prices slid again overnight to fall to a more than two-month low at US$65.63 a barrel of Brent, recovering only marginally this morning. Gold futures moved in the other direction, adding 0.3% to US$3408.30 an ounce, still hovering in a tight band between US$3300 and US$3450. Spot gold is trading at about US$3371 per ounce. Things are looking fairly quiet on the small cap movers front in terms of announcements today, perhaps a sign market fundamentals are driving growth just as much as company news this morning. SMALL CAP WINNERS Code Name Last % Change Volume Market Cap GGE Grand Gulf Energy 0.002 100% 800584 $2,820,425 BPP Babylon Pump & Power 0.007 40% 7620771 $19,034,455 MGTRG Magnetite Mines 0.007 40% 259119 $204,263 CR9 Corellares 0.004 33% 750000 $3,021,809 TYX Tyranna Res Ltd 0.004 33% 250000 $10,026,464 FRB Firebird Metals 0.18 29% 650077 $19,930,596 OD6 Od6Metalsltd 0.086 26% 6409968 $10,911,821 ATV Activeport Group Ltd 0.012 26% 9876084 $6,526,282 DTM Dart Mining NL 0.0025 25% 550000 $2,396,111 KNG Kingsland Minerals 0.175 21% 164868 $10,521,332 In the news... Activeport (ASX:ATV) has secured three private cloud hosts for its newly launched fibre-based network-as-a-service product, Private-Cloud Connect. Available from this month, the product is designed to offer high speed data communication ports, connecting branch offices to private cloud services hosted in colocation data centres. With demand for data centre capacity ramping up sharply alongside demand for AI applications, ATV is positioning itself to provide the network services necessary to support the emerging technologies. SMALL CAP LAGGARDS Code Name Last % Change Volume Market Cap HLX Helix Resources 0.001 -40% 5454451 $5,606,765 CZN Corazon Ltd 0.002 -33% 100500 $3,703,717 LMLR Lincoln Minerals 0.002 -33% 2642857 $937,101 SHP South Harz Potash 0.002 -33% 675 $4,415,170 AOA Ausmon Resorces 0.0015 -25% 270339 $2,622,427 ECT Env Clean Tech Ltd. 0.003 -25% 38353 $16,061,742 PKO Peako Limited 0.003 -25% 10500000 $5,950,968 SFG Seafarms Group Ltd 0.0015 -25% 8132 $9,673,198 1AD Adalta Limited 0.002 -20% 102173 $2,886,625 EMT Emetals Limited 0.005 -17% 120000 $5,100,000 This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Top 10 at 11: ASX bounces back; ATV launches network cloud product
